BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 21707510)

  • 1. A novel small molecule inhibitor of FAK and IGF-1R protein interactions decreases growth of human esophageal carcinoma.
    Ucar DA; Cox A; He DH; Ostrov DA; Kurenova E; Hochwald SN
    Anticancer Agents Med Chem; 2011 Sep; 11(7):629-37. PubMed ID: 21707510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibiting the interaction of cMET and IGF-1R with FAK effectively reduces growth of pancreatic cancer cells in vitro and in vivo.
    Ucar DA; Magis AT; He DH; Lawrence NJ; Sebti SM; Kurenova E; Zajac-Kaye M; Zhang J; Hochwald SN
    Anticancer Agents Med Chem; 2013 May; 13(4):595-602. PubMed ID: 23272972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disruption of the protein interaction between FAK and IGF-1R inhibits melanoma tumor growth.
    Ucar DA; Kurenova E; Garrett TJ; Cance WG; Nyberg C; Cox A; Massoll N; Ostrov DA; Lawrence N; Sebti SM; Zajac-Kaye M; Hochwald SN
    Cell Cycle; 2012 Sep; 11(17):3250-9. PubMed ID: 22894899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells.
    Liu W; Bloom DA; Cance WG; Kurenova EV; Golubovskaya VM; Hochwald SN
    Carcinogenesis; 2008 Jun; 29(6):1096-107. PubMed ID: 18263593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TAE226, a dual inhibitor for FAK and IGF-IR, has inhibitory effects on mTOR signaling in esophageal cancer cells.
    Wang ZG; Fukazawa T; Nishikawa T; Watanabe N; Sakurama K; Motoki T; Takaoka M; Hatakeyama S; Omori O; Ohara T; Tanabe S; Fujiwara Y; Shirakawa Y; Yamatsuji T; Tanaka N; Naomoto Y
    Oncol Rep; 2008 Dec; 20(6):1473-7. PubMed ID: 19020730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological profiling of a dual FAK/IGF-1R kinase inhibitor TAE226 in cellular and in vivo tumor models.
    Fukami S; Tomioka D; Murakami Y; Honda T; Hatakeyama S
    BMC Res Notes; 2019 Jun; 12(1):347. PubMed ID: 31215459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor exhibits anticancer effect in esophageal adenocarcinoma in vitro and in vivo.
    Watanabe N; Takaoka M; Sakurama K; Tomono Y; Hatakeyama S; Ohmori O; Motoki T; Shirakawa Y; Yamatsuji T; Haisa M; Matsuoka J; Beer DG; Nagatsuka H; Tanaka N; Naomoto Y
    Clin Cancer Res; 2008 Jul; 14(14):4631-9. PubMed ID: 18628478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Id1-induced IGF-II and its autocrine/endocrine promotion of esophageal cancer progression and chemoresistance--implications for IGF-II and IGF-IR-targeted therapy.
    Li B; Tsao SW; Chan KW; Ludwig DL; Novosyadlyy R; Li YY; He QY; Cheung AL
    Clin Cancer Res; 2014 May; 20(10):2651-62. PubMed ID: 24599933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways.
    Dayyani F; Parikh NU; Varkaris AS; Song JH; Moorthy S; Chatterji T; Maity SN; Wolfe AR; Carboni JM; Gottardis MM; Logothetis CJ; Gallick GE
    PLoS One; 2012; 7(12):e51189. PubMed ID: 23300537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells.
    Zhang J; He DH; Zajac-Kaye M; Hochwald SN
    Cell Cycle; 2014; 13(19):3143-9. PubMed ID: 25486573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo.
    Liu TJ; LaFortune T; Honda T; Ohmori O; Hatakeyama S; Meyer T; Jackson D; de Groot J; Yung WK
    Mol Cancer Ther; 2007 Apr; 6(4):1357-67. PubMed ID: 17431114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin-like growth factor-1 receptor and ErbB kinase inhibitor combinations block proliferation and induce apoptosis through cyclin D1 reduction and Bax activation.
    Wilsbacher JL; Zhang Q; Tucker LA; Hubbard RD; Sheppard GS; Bamaung NY; Fidanze SD; Wang GT; Hu X; Davidsen SK; Bell RL; Wang J
    J Biol Chem; 2008 Aug; 283(35):23721-30. PubMed ID: 18559346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer.
    Hochwald SN; Nyberg C; Zheng M; Zheng D; Wood C; Massoll NA; Magis A; Ostrov D; Cance WG; Golubovskaya VM
    Cell Cycle; 2009 Aug; 8(15):2435-43. PubMed ID: 19571674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual sphingosine kinase inhibitor SKI-II enhances sensitivity to 5-fluorouracil in hepatocellular carcinoma cells via suppression of osteopontin and FAK/IGF-1R signalling.
    Grbčić P; Tomljanović I; Klobučar M; Kraljević Pavelić S; Lučin K; Sedić M
    Biochem Biophys Res Commun; 2017 Jun; 487(4):782-788. PubMed ID: 28433634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer.
    Becker MA; Hou X; Tienchaianada P; Haines BB; Harrington SC; Weroha SJ; Sathyanarayanan S; Haluska P
    BMC Cancer; 2016 Oct; 16(1):814. PubMed ID: 27765027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association of TP53 mutations with the resistance of colorectal carcinoma to the insulin-like growth factor-1 receptor inhibitor picropodophyllin.
    Wang Q; Wei F; Lv G; Li C; Liu T; Hadjipanayis CG; Zhang G; Hao C; Bellail AC
    BMC Cancer; 2013 Nov; 13():521. PubMed ID: 24182354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bit1 knockdown contributes to growth suppression as well as the decreases of migration and invasion abilities in esophageal squamous cell carcinoma via suppressing FAK-paxillin pathway.
    Fan T; Chen J; Zhang L; Gao P; Hui Y; Xu P; Zhang X; Liu H
    Mol Cancer; 2016 Mar; 15():23. PubMed ID: 26956728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ERK phosphorylation is predictive of resistance to IGF-1R inhibition in small cell lung cancer.
    Zinn RL; Gardner EE; Marchionni L; Murphy SC; Dobromilskaya I; Hann CL; Rudin CM
    Mol Cancer Ther; 2013 Jun; 12(6):1131-9. PubMed ID: 23515613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin-like growth factor-1 receptor as a novel prognostic marker and its implication as a cotarget in the treatment of human adenocarcinoma of the esophagus.
    Kalinina T; Bockhorn M; Kaifi JT; Thieltges S; Güngör C; Effenberger KE; Strelow A; Reichelt U; Sauter G; Pantel K; Izbicki JR; Yekebas EF
    Int J Cancer; 2010 Oct; 127(8):1931-40. PubMed ID: 20104520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cells.
    Meyer GE; Chesler L; Liu D; Gable K; Maddux BA; Goldenberg DD; Youngren JF; Goldfine ID; Weiss WA; Matthay KK; Rosenthal SM
    J Cell Biochem; 2007 Dec; 102(6):1529-41. PubMed ID: 17486636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.